Active Surveillance in Prostate Cancer

Active surveillance is a structured follow-up strategy used in selected people with prostate cancer, especially when the disease appears low risk and immediate treatment may not be necessary. It does not mean ignoring the cancer. Instead, it means monitoring it closely so that treatment can begin if the disease shows signs of becoming more concerning. ^[1][2][3]

What does active surveillance mean?

In active surveillance, the aim is to avoid or delay surgery or radiation when the cancer appears unlikely to cause harm in the near term, while still maintaining careful observation. This strategy can help preserve quality of life by reducing exposure to treatment side effects such as urinary, bowel, or sexual-function problems in people whose cancer may remain slow growing for a long period. ^[1][2][4]

Who may be a candidate?

Active surveillance is most often discussed in people with low-risk or otherwise favorable prostate cancer features. Suitability depends on factors such as PSA level, biopsy findings, imaging, tumor grade, age, overall health, and personal priorities. Not every person with prostate cancer is an appropriate candidate. Higher-risk disease, more aggressive pathology, or a clinical picture suggesting faster progression may lead clinicians to recommend active treatment instead. ^[2][3]

Is active surveillance the same as watchful waiting?

No. Active surveillance and watchful waiting are not identical. Active surveillance is a structured program with regular testing and the possibility of curative treatment if progression is detected. Watchful waiting is generally less intensive and may focus more on symptom control, often in situations where cure is not the primary goal. Confusing the two can lead to misunderstanding about how closely the cancer is actually being monitored. ^[1][2][3]

What are the advantages?

The main advantage of active surveillance is that it may help a person avoid or postpone treatment-related side effects without abandoning medical follow-up. In the right patient, this can mean maintaining urinary, sexual, and bowel function for longer while still preserving the option of curative treatment if the cancer changes. It also recognizes that not all prostate cancers behave in the same way and that some are more indolent than others. ^[2][3][4]

What are the disadvantages and risks?

The disadvantages include anxiety related to living with a known cancer, the burden of repeat tests and biopsies, and the possibility that some cancers may evolve over time. Although active surveillance is designed to detect change early, it still requires adherence and clear communication. It is not the same as guaranteeing that the disease will never progress. ^[2][3]

What happens in the follow-up plan?

Follow-up usually includes regular PSA testing, repeat clinical assessment, and in many programs repeat MRI and/or repeat biopsy at intervals determined by the care team. The exact schedule varies. The key point is that active surveillance is an organized program, not a vague suggestion to “just wait.” When follow-up is not maintained, the strategy becomes less safe. ^[2][3][4]

When is re-evaluation needed?

Re-evaluation is needed if PSA behavior changes, MRI findings become more concerning, biopsy results show progression, symptoms develop, or the patient’s preferences change. Active surveillance is an ongoing decision rather than a one-time label. A person may remain on surveillance for years, or the plan may change if the balance of risk and benefit shifts. ^[2][3]